Business Context and Reporting Period
This Form 8-K Current Report was filed by Acadia Pharmaceuticals Inc. on October 28, 2025, regarding events occurring on that date. The report addresses corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding officer departures and does not contain financial statements or operational metrics.
Material Changes
The primary material change reported is the resignation of Daniel B. Soland from the Board of Directors and his role as Chair of the Nominating and Corporate Governance Committee. The resignation is effective as of October 30, 2025. The Company explicitly states that the resignation was not the result of any dispute or disagreement regarding the Company's operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary on future guidance, outlook, or specific risks. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Confirm the effective date of Daniel B. Soland's resignation (October 30, 2025).
- Verify if a replacement director or committee chair has been appointed in subsequent filings.
- Review the Company's most recent 10-K or 10-Q for current financial health, as this 8-K contains no financial data.